Scholar Rock (NASDAQ:SRRK) Given Outperform Rating at Wedbush

Wedbush reiterated their outperform rating on shares of Scholar Rock (NASDAQ:SRRKFree Report) in a research note published on Wednesday morning,RTT News reports. They currently have a $50.00 target price on the stock.

Separately, Lifesci Capital raised Scholar Rock to a “strong-buy” rating in a research report on Tuesday, June 3rd. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $42.67.

Read Our Latest Report on Scholar Rock

Scholar Rock Stock Up 16.6%

SRRK stock opened at $36.32 on Wednesday. Scholar Rock has a twelve month low of $6.76 and a twelve month high of $46.98. The company has a quick ratio of 10.25, a current ratio of 10.25 and a debt-to-equity ratio of 0.16. The stock has a market cap of $3.45 billion, a P/E ratio of -14.36 and a beta of 0.28. The business’s 50-day moving average price is $31.32 and its 200-day moving average price is $36.09.

Scholar Rock (NASDAQ:SRRKGet Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.04). During the same quarter in the previous year, the firm earned ($0.59) earnings per share. On average, equities research analysts forecast that Scholar Rock will post -2.42 EPS for the current year.

Insider Activity at Scholar Rock

In related news, Director Kristina Burow sold 5,400 shares of Scholar Rock stock in a transaction that occurred on Thursday, May 29th. The stock was sold at an average price of $29.72, for a total transaction of $160,488.00. Following the sale, the director now owns 21,071 shares of the company’s stock, valued at approximately $626,230.12. This trade represents a 20.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Tracey Sacco sold 6,500 shares of Scholar Rock stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $33.08, for a total value of $215,020.00. Following the completion of the sale, the insider now directly owns 71,750 shares in the company, valued at approximately $2,373,490. The trade was a 8.31% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,500 shares of company stock valued at $1,181,671. 13.30% of the stock is owned by company insiders.

Institutional Trading of Scholar Rock

Large investors have recently added to or reduced their stakes in the company. Global Retirement Partners LLC increased its stake in Scholar Rock by 584.7% in the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock worth $39,000 after acquiring an additional 766 shares during the last quarter. CWM LLC increased its stake in Scholar Rock by 152.8% in the 1st quarter. CWM LLC now owns 996 shares of the company’s stock worth $32,000 after acquiring an additional 602 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in Scholar Rock in the 4th quarter worth approximately $85,000. Federated Hermes Inc. bought a new stake in Scholar Rock in the 1st quarter worth approximately $71,000. Finally, Strs Ohio bought a new stake in Scholar Rock in the 1st quarter worth approximately $77,000. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Company Profile

(Get Free Report)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

Further Reading

Analyst Recommendations for Scholar Rock (NASDAQ:SRRK)

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.